(3-(5-Methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid → (1-Methyl-cyclohexyl)-{2-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenyl]-5H-pyrrolo[2,3-b]pyrazin-7-yl}-methanone

Participants

Role	Name	HCID	Charge
Reactant	(3-(5-Methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid	HCID 44119380	—
Reactant	(2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-(1-methyl-cyclohexyl)-methanone	HCID 44199730	—
Product	(1-Methyl-cyclohexyl)-{2-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenyl]-5H-pyrrolo[2,3-b]pyrazin-7-yl}-methanone	HCID 59540696	—

Reaction Steps

(1-Methyl-cyclohexyl)-{2-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenyl]-5H-pyrrolo[2,3-b]pyrazin-7-yl}-methanone was prepared starting from (2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-(1-methyl-cyclohexyl)-methanone and 3-(5-Methyl-1,3,4-oxadiazol-2-yl)phenylboronic acid following general procedures as described in these Examples. MP 234-236° C., M+H=402.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US08008298B2
Source dataset	uspto-grants-2011_08
ORD ID	ord-037c0e5e41144cfbb44417326a963d73
Source note	uspto-grants-2011_08